Cornell's Center for Technology Licensing (CTL)

Issue 02 – September 2026

Cornell Discovery to Impact

Technology commercialization in action

The path from a lab discovery to a product on the market is rarely straight. It takes funding, risk, patience, and — more often than not — a community of people willing to help move it forward. Each issue of Cornell Discovery to Impact follows that path.

We're also excited to welcome Matt Marx, Cornell's new Vice Provost for Entrepreneurship, Innovation, and External Engagement. Matt brings deep experience at the intersection of research and commercialization, and his appointment signals just how central this work has become to Cornell's future. We're looking forward to what's ahead with him in this role.


Thank you for being here!

Alice Li

Executive Director

Center for Technology Licensing (CTL)

Lisa Placanica

Senior Managing Director at CTL at

Weill Cornell Medicine

 

In This Issue

🧬 Kanvas Biosciences: from Cornell lab to $48M Series A

🔥 Gap funding impact: Cornell-affiliated startups secure funding

✨ The journey from lab to market

🚀 Startups to watch: Ratio Therapeutics and Soctera

🤝 Technologies available for partnership

💡 Bearers of Innovation keynote and fireside chat

📣 New faces at CTL

📅 Engage with us

 
 

Kanvas Biosciences: From a Cornell Lab to $48 Million Series A

Hao Shi Ph.D. ’20, and Iwijn De Vlaminck, associate professor of biomedical engineering, executives in the new company Kanvas Biosciences.

Professor Iwijn De Vlaminck and Hao Shi, Ph.D., co-founders of Kanvas Bioscience. Matt Cheng (not pictured) is also a co-founder.

Kanvas Biosciences closed a $48 million Series A round that will fund a clinical trial later this year for its lead cancer immunotherapy. The company's platform is built on HiPR-FISH, a microbiome imaging technology licensed through CTL that maps how gut bacteria interact with the human body in unprecedented detail. Kanvas is also advancing therapies for inflammation and malnutrition-related gut disease, including a partnership with the Gates Foundation.

Interested in Cornell's life sciences and biotech innovations? Connect with our team to explore opportunities.

 
 
 

Gap Funding Impact

Cornell-affiliated startups secure Ignite gap funding to advance commercialization

Four-panel collage of Ignite Startup Projects awardees — IVSonance co-founders Nicole Lustgarten and Amir Mokhtare, Lucentia founder Sahar Jalal, Quantera founder Terry Bates, and SensVita co-founder Thomas Conroy.

From left: IVSonance's Nicole Lustgarten and Amir Mokhtare, Lucentia's Sahar Jalal, Quantera's Terry Bates, and SensVita's Thomas Conroy.

Most early technology companies hit a gap between initial validation and the milestones needed to scale. In FY2026, Ignite Startup Projects awarded four Cornell-affiliated startups—IVSonance, Lucentia, Quantera Analytical Services, and SensVita—$75,000 each to help support that work, from FDA validation to lab build-out. Since 2018, the program has backed 36 startups, two of which have already been acquired.

Ready to advance your technology? Explore gap funding opportunities at every stage:

 
 
 

The Journey from Lab to Market

Ronald Crystal

Dr. Ronald Crystal's Phase 1 clinical trial shows gene therapy is safe for inherited heart disease

Drs. Alex Travis and Roy Cohen, co-founders of TETmedical, in their laboratory at Cornell's Baker Institute, with microscopy equipment visible in the background.

Dr. Alex Travis and Roy Cohen's blood test for stroke earns FDA Breakthrough Device Designation

🔗 Explore more commercialization stories

 

Startups to watch

 
Ratio Therapeutics Nasdaq announcement

Ratio Therapeutics Closes $70M Series C


Ratio Therapeutics, a Weill Cornell Medicine startup, closed a $70 million Series C to advance its clinical-stage radiopharmaceutical pipeline for cancer treatment.

Soctera team in the lab

Soctera Raises $4M to Advance Power Amplifiers


Soctera, which spun out of Cornell's Jena-Xing lab, raised $4 million in seed funding to develop power amplifiers for defense and space systems.

 

Technologies available for partnership

 
Abstract illustration of a molecular network showing interconnected red nodes of varying sizes on a teal background, representing protein-ligand binding interactions mapped across a biological system.

Affinity Map: A platform to uncover how medicines interact with proteins in the body


Developing drugs with specificity and selectivity for a target is essential to developing new medicines. Affinity Map lets researchers measure how strongly a drug candidate interacts with proteins across an entire biological sample at once, faster and with more resolution than existing methods.

Flat vector illustration of a red circuit board with interconnected pathways, microchips, and electronic components on a light gray background, representing AI computing hardware.

Precision+: More AI performance. Same chips. No new hardware.


AI models require significant computing resources to run, and much of that cost comes down to how numbers are processed. This technology improves AI chip efficiency by using a previously unused numerical value, delivering better performance without additional hardware.

Explore Cornell's portfolio of technologies available for licensing and industry collaboration.


Search available technologies →

 

Bearers of Innovation: A One Cornell Celebration

 

Celebrating the inventors behind the inventions

CTL brought together inventors from across colleges and campuses in Ithaca and at Weill Cornell Medicine for Bearers of Innovation: A One Cornell Celebration. Watch the keynote and the fireside chat below.

Keynote speakers Robert Van Renesse and Hakim Weatherspoon headshots

Keynote by Robert Van Renesse and Hakim Weatherspoon, founders of Exostellar recently acquired by Qualcomm.

Fireside chat speaker Jason Spector

Fireside chat with Jason Spector, MD, founder of Fesarius Therapeutics, a Weill Cornell spinout treating full-thickness skin loss.

 

New faces at CTL

 

The CTL team has two new members in the business development & licensing team ready to work with Cornell researchers, inventors and industry partners.

Paul Debbie, Associate Director at Cornell's Center for Technology Licensing, in a professional headshot with a Cornell red background.

Paul Debbie

Associate Director, Business Development & Licensing


Meet Paul ➜

Dezi Elzinga, Business Development and Licensing team member at Cornell's Center for Technology Licensing, in a professional headshot with a Cornell red background.

Dezi Elzinga

Business Development & Licensing Associate


Meet Dezi ➜

 

Meet the CTL team or book office hours with a business development and licensing professional.

 

Engage with Us

 

Where Cornell innovations meet expert feedback

Cornell Innovation & Venture Advisors (CIVA) banner

Cornell Innovation & Venture Advisors (CIVA)

  • For industry and investors: Join the CIVA network to access Cornell innovations and share your expert feedback as an advisor.
  • For Cornell inventors: Present your innovation at the next CIVA roundtable.


Upcoming dates: December 8 | February 9 | May 11


Request your invitation: Email Kris Behnke to join as an advisor or to be considered as a presenter.

Learn more about CIVA →

Explore our upcoming events

Discover additional opportunities for inventors and industry to connect, collaborate and engage with CTL and Cornell's innovation ecosystem.


View upcoming events →

 

Stay Connected

 

Was this email forwarded to you? Sign up for our newsletter →

Follow us on social:

LinkedIn  YouTube  X

Work with us:

Email  Web
 
 
 
Research & Innovation
Weill Cornell Medicine Enterprise Innovation